Small extracellular vesicle-based one-step high-throughput microfluidic platform for epithelial ovarian cancer diagnosis DOI Creative Commons
Yu Wu, Chao Wang, Yukun Guo

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 7, 2025

Ovarian cancer (OC) is diagnosed at advanced stages, resulting in limited treatment options for patients. While early detection of OC has been investigated, the invasiveness approaches, high sample requirements, or false-positive rates undermined its benefits. Here, we present a "one-step" high-throughput microfluidic platform epithelial ovarian (EOC) that integrates small extracellular vesicle (sEV) capture, situ lysis, and protein biomarker detection. We identified 1,818 differentially expressed proteins (DEPs) through proteomic analysis sEVs from patients' serum, combined with cell lines. Through multi-step screening DEPs, EOC biomarkers to customize platform. used test expression 2 µL serum 209 participants prospective cohort. Based on results, an model (P9) was constructed, which achieved sensitivity 92.3% (95% CI, 75.9-97.9%) stage I, 90.0% 69.9-97.2%) II specificity 98.8% 93.6-99.8%) training set. The specificities reached set 100.0% 91.6-100.0%) validation held-out group 105 participants. A combining P9 patient's CA125 value exhibited 95.6-100%) both validation, without compromising sensitivity. developed non-invasive sEV-derived It significantly reduced false positives volume. Given convenience low cost, this could advance benefit women.

Language: Английский

Small extracellular vesicle-based one-step high-throughput microfluidic platform for epithelial ovarian cancer diagnosis DOI Creative Commons
Yu Wu, Chao Wang, Yukun Guo

et al.

Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 7, 2025

Ovarian cancer (OC) is diagnosed at advanced stages, resulting in limited treatment options for patients. While early detection of OC has been investigated, the invasiveness approaches, high sample requirements, or false-positive rates undermined its benefits. Here, we present a "one-step" high-throughput microfluidic platform epithelial ovarian (EOC) that integrates small extracellular vesicle (sEV) capture, situ lysis, and protein biomarker detection. We identified 1,818 differentially expressed proteins (DEPs) through proteomic analysis sEVs from patients' serum, combined with cell lines. Through multi-step screening DEPs, EOC biomarkers to customize platform. used test expression 2 µL serum 209 participants prospective cohort. Based on results, an model (P9) was constructed, which achieved sensitivity 92.3% (95% CI, 75.9-97.9%) stage I, 90.0% 69.9-97.2%) II specificity 98.8% 93.6-99.8%) training set. The specificities reached set 100.0% 91.6-100.0%) validation held-out group 105 participants. A combining P9 patient's CA125 value exhibited 95.6-100%) both validation, without compromising sensitivity. developed non-invasive sEV-derived It significantly reduced false positives volume. Given convenience low cost, this could advance benefit women.

Language: Английский

Citations

0